A basic science view of acute kidney injury biomarkers

Nephrology Dialysis Transplantation

Volumn 29, Issue 7, 2014, Pages 1301-1311

  Charlton, Jennifer R ^a   Portilla, Didier ^b   Okusa, Mark D ^a,c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Acute renal failure; Cystatin C; IL 18; KIM 1; NGAL

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CYSTATIN C; FATTY ACID BINDING PROTEIN; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; LIVER FATTY ACID BINDING PROTEIN; N ACETYL BETA GLUCOSAMINIDASE; NETRIN; NETRIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SOMATOMEDIN BINDING PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; CELL CYCLE; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HUMAN; MICROALBUMINURIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN URINE LEVEL; REVIEW; URINARY EXCRETION;

ACUTE RENAL FAILURE; CYSTATIN-C; IL-18; KIM-1; NGAL;

ACUTE KIDNEY INJURY; ANIMALS; BIOLOGICAL MARKERS; HUMANS;

EID: 84897528641     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft510     Document Type: Review

References (122)

1. Hsu RK, McCulloch CE, Dudley RA et al. Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol 2013.; 24: 37-42
2. Bonventre JV, Basile D, Liu KD et al. AKI: A path forward. Clin J Am Soc Nephrol 2013.; 8: 1606-1608
3. Jo SK, Rosner MH, Okusa MD. Pharmacologic treatment of acute kidney injury. Why drugs haven't: Why drugs haven't worked and what is on the horizon. Clin J Am Soc Nephrol 2007.; 2: 256-365
4. Bellomo R, Ronco C, Kellum JA et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004.; 8: R204YR212
5. Mehta RL, Kellum JA, Shah SV et al. Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007.; 11: R31
6. Singbartl K, Kellum JA. AKI in the ICU: Definition, epidemiology, risk stratification, and outcomes. Kidney Int 2012.; 81: 819-825
7. Nickolas TL, Schmidt-Ott KM, Canetta P et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: A multicenter prospective cohort study. J Am Coll Cardiol 2012.; 59: 246-255
8. Endre ZH, Walker RJ, Pickering JW et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010.; 77: 1020-1030
9. Murray PT, Mehta RL, Shaw A et al. Current use of biomarkers in acute kidney injury: Report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int 2013 doi: 10.1038/ki.2013.374
10. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008.; 48: 463-493
11. Ostermann M, Philips BJ, Forni LG. Clinical review: Biomarkers of acute kidney injury: Where are we now? Crit Care 2012.; 16: 233
12. Waikar SS, Sabbisetti VS, Bonventre JV. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int 2010.; 78: 486-494
13. Ralib AM, Pickering JW, Shaw GM et al. Test characteristics of urinary biomarkers depend on quantitation method in acute kidney injury. J Am Soc Nephrol 2012.; 23: 322-333
14. Clausen J. Proteins in normal cerebrospinal fluid not found in serum. Proc Soc Exp Biol Med 1961.; 107: 170-172
15. Macpherson CF, Cosgrove JB. Immunochemical evidence for a gamma globulin peculiar to cerebrospinal fluid. Can J Biochem Physiol 1961.; 39: 1567-1574
16. Butler EA, Flynn FV. The occurrence of post-gamma protein in urine: A new protein abnormality. J Clin Pathol 1961.; 14: 172-178
17. Barrett AJ, Davies ME, Grubb A. The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochem Biophys Res Commun 1984.; 120: 631-636
18. Brzin J, Popovic T, Turk V et al. Human cystatin, a new protein inhibitor of cysteine proteinases. Biochem Biophys Res Commun 1984.; 118: 103-109
19. Kaseda R, Iino N, Hosojima M et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells. Biochem Biophys Res Commun 2007.; 357: 1130-1134
20. Vanmassenhove J, Vanholder R, Nagler E et al. Urinary and serum biomarkers for the diagnosis of acute kidney injury: An in-depth review of the literature. Nephrol Dial Transplant 2013.; 28: 254-273
21. Amsellem S, Gburek J, Hamard G et al. Cubilin is essential for albumin reabsorption in the renal proximal tubule. J Am Soc Nephrol 2010.; 21: 1859-1867
22. Nejat M, Hill JV, Pickering JW et al. Albuminuria increases cystatin C excretion: Implications for urinary biomarkers. Nephrol Dial Transplant 2012.; 27(Suppl. 3): Iii96Yii103
23. Herget-Rosenthal S, Bokenkamp A, Hofmann W. How to estimate GFRserum creatinine, serum cystatin C or equations? Clin Biochem 2007.; 40: 153-161
24. Seronie-Vivien S, Delanaye P, Pieroni L et al. Cystatin C: Current position and future prospects. Clin Chem Lab Med 2008.; 46: 1664-1686
25. Togashi Y, Sakaguchi Y, Miyamoto M et al. Urinary cystatin C as a biomarker for acute kidney injury and its immunohistochemical localization in kidney in the CDDP-treated rats. Exp Toxicol Pathol 2012.; 64: 797-805
26. Sasaki D, Yamada A, Umeno H et al. Comparison of the course of biomarker changes and kidney injury in a rat model of drug-induced acute kidney injury. Biomarkers 2011.; 16: 553-566
27. Spahillari A, Parikh CR, Sint K et al. Serum cystatin C- versus creatininebased definitions of acute kidney injury following cardiac surgery: A prospective cohort study. Am J Kidney Dis 2012.; 60: 922-929
28. Hassinger AB, Backer CL, Lane JC et al. Predictive power of serum cystatin C to detect acute kidney injury and pediatric-modified RIFLE class in children undergoing cardiac surgery. Pediatr Crit Care Med 2012.; 13: 435-440
29. Royakkers AA, Korevaar JC, van Suijlen JD et al. Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy. Intensive Care Med 2011.; 37: 493-501
30. Soto K, Coelho S, Rodrigues B et al. Cystatin C as a marker of acute kidney injury in the emergency department. Clin J Am Soc Nephrol 2010.; 5: 1745-1754
31. Ferguson MA VV, Bonventre JV. Biomarkers of nephrotoxic acute kindey injury. Toxicology 2008.; 245: 182-193
32. Ware JB JA, Zager RA. Renal cortical albumin gene induction and urinary albumin excretion in response to acute kidney injury. Am J Physiol Renal Physiol 2011.; 300: F628YF638
33. Rached E, Hoffmann D, Blumbach K et al. Evaluation of putative biomarkers of nephrotoxicity after exposure to ochratoxin a in vivo and in vitro. Toxicol Sci 2008.; 103: 371-381
34. Xu C, Chang A, Hack BK et al. TNF-mediated damage to glomerular endothelium is an important determinant of acute kidney injury in sepsis. Kidney Int 2013.; doi: 10.1038/ki.2013.286
35. Koch Nogueira PC, Hadj-Aissa A, Schell M et al. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr Nephrol 1998.; 12: 572-575
36. KernW, Braess J, Kaufmann CC et al. Microalbuminuria during cisplatin therapy: Relation with pharmacokinetics and implications for nephroprotection. Anticancer Res 2000.; 20: 3679-3688
37. Tugay S, Bircan Z, Caglayan C et al. Acute effects of gentamicin on glomerular and tubular functions in preterm neonates. Pediatr Nephrol 2006.; 21: 1389-1392
38. Zappitelli M, Coca SG, Garg AX et al. The association of albumin/creatinine ratio with postoperative AKI in children undergoing cardiac surgery. Clin J Am Soc Nephrol 2012.; 7: 1761-1769
39. Zheng J, Xiao Y, Yao Y et al. Comparison of urinary biomarkers for early detection of acute kidney injury after cardiopulmonary bypass surgery in infants and young children. Pediatr Cardiol 2013.; 34: 880-886
40. Brinkman JW, de Zeeuw D, Lambers Heerspink HJ et al. Apparent loss of urinary albumin during long-term frozen storage: HPLC vs immunonephelometry. Clin Chem 2007.; 53: 1520-1526
41. Brinkman JW, de Zeeuw D, Duker JJ et al. Falsely low urinary albumin concentrations after prolonged frozen storage of urine samples. Clin Chem 2005.; 51: 2181-2183
42. Waring WS, Moonie A. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol (Phila) 2011.; 49: 720-728
43. Li J, Li QX, Xie XF et al. Differential roles of dihydropyridine calcium antagonist nifedipine, nitrendipine and amlodipine on gentamicininduced renal tubular toxicity in rats. Eur J Pharmacol 2009.; 620: 97-104
44. Xu Z, Yang J, Yu J et al. Effects of BSO, GSH, Vit-C and DMPS on the nephrotoxicity of mercury. Toxicol Ind Health 2007.; 23: 403-410
45. Ali BH, Al Moundhri MS, Tag Eldin M et al. The ameliorative effect of cysteine prodrug L-2-oxothiazolidine-4-carboxylic acid on cisplatininduced nephrotoxicity in rats. Fundam Clin Pharmacol 2007.; 21: 547-553
46. Westhuyzen J, Endre ZH, Reece G et al. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant 2003.; 18: 543-551
47. Chew SL, Lins RL, Daelemans R et al. Urinary enzymes in acute renal failure. Nephrol Dial Transplant 1993.; 8: 507-511
48. Bondiou MT, Bourbouze R, Bernard M et al. Inhibition of A and B Nacetyl- beta-D-glucosaminidase urinary isoenzymes by urea. Clin Chim Acta 1985.; 149: 67-73
49. Vaidya VS, Ramirez V, Ichimura T et al. Urinary kidney injury molecule- 1 (Kim-1): A sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2005
50. Iqbal MP, Ali AA, Waqar MA et al. Urinary N-Acetyl-beta-D-glucosaminidase in rheumatoid arthritis. Exp Mol Med 1998.; 30: 165-169
51. Fujita H, Narita T, Morli T et al. Increased urinary excretion of N-Acetyglucosaminidase in subjects with impaired glucose tolerance. Ren Fail 2002.; 24: 69-75
52. Tominaga M, Fujiyama K, Hoshino T et al. Urinary N-Acetyl-beta-D- glucosaminidase in the patients with hyperthyroidism. Horm Metab Res 1989.; 21: 438-440
53. Nauta FL, Bakker SJ, Lambers Heerspink H et al. Effect of frozen storage on urinary concentration of kidney damage markers. Am J Kidney Dis 2012.; 59: 586-589
54. Ichimura T, Bonventre JV, Bailly V et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998.; 13: 4135-4142
55. Bailly V, Zhang Z, Meier Wet al. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem 2002.; 277: 39739-39748
56. Ichimura T, Brooks CR, Bonventre JV. Kim-1/Tim-1 and immune cells: Shifting sands. Kidney Int 2012.; 81: 809-811
57. Ichimura T, Asseldonk EJ, Humphreys BD et al. Kidney injury molecule- 1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 2008.; 118: 1657-1668
58. Han WK, Bailly V, Abichandani R et al. Kidney injury molecule-1 (KIM- 1): A novel biomarker for human renal proximal tubule injury. Kidney Int 2002.; 62: 237-244
59. Ichimura T, Hung CC, Yang SA et al. Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 2004.; 286: F552YF563
60. Lim AI, Tang SC, Lai KN et al. Kidney injury molecule-1: More than just an injury marker of tubular epithelial cells? J Cell Physiol 2013.; 228: 917-924
61. Slocum JL, Heung M, Pennathur S. Marking renal injury: Can we move beyond serum creatinine? Transl Res 2012.; 159: 277-289
62. Huang Y, Don-Wauchope AC. The clinical utility of kidney injury molecule 1 in the prediction, diagnosis and prognosis of acute kidney injury: A systematic review. Inflamm Allergy Drug Targets 2011.; 10: 260-271
63. Sabbisetti VS, Ito K, Wang C et al. Novel assays for detection of urinary KIM-1 in mouse models of kidney injury. Toxicol Sci 2013.; 131: 13-25
64. Dieterle f, sistare f, goodsaid f et al. Renal biomarker qualification submission: A dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol 2010.; 28: 455-462
65. Kjeldsen L, Johnsen AH, Sengelov H et al. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993.; 268: 10425-10432
66. Kjeldsen SE, Schork NJ, Leren P et al. Arterial plasma norepinephrine correlates to blood pressure in middle-Aged men with sustained essential hypertension. Am Heart J. 1989.; 118: 775-781
67. Goetz DH, Willie ST, Armen RS et al. Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 2000.; 39: 1935-1941
68. Cai L, Rubin J, Han W et al. The origin of multiple molecular forms in urine of HNL/NGAL. Clin J Am Soc Nephrol 2010.; 5: 2229-2235
69. Kuwabara T, Mori K, Mukoyama M et al. Urinary neutrophil gelatinaseassociated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 2009.; 75: 285-294
70. Hvidberg V, Jacobsen C, Strong RK et al. The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-Associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett 2005.; 579: 773-777
71. Mishra J, Ma Q, Prada A et al. Identification of neutrophil gelatinase-Associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003.; 14: 2534-2543
72. Mishra J, Mori K, Ma Q et al. Neutrophil gelatinase-Associated lipocalin: A novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004.; 24: 307-315
73. Mishra J, Dent C, Tarabishi R et al. Neutrophil gelatinase-Associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005.; 365: 1231-1238
74. Paragas N, Qiu A, Hollmen M et al. NGAL-siderocalin in kidney disease. Biochim Biophys Acta 2012.; 1823: 1451-1458
75. Haase M, Bellomo R, Devarajan P et al. Accuracy of neutrophil gelatinase- associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: A systematic review and meta-Analysis. Am J Kidney Dis 2009.; 54: 1012-1024
76. Paragas N, Qiu A, Zhang Q et al. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nature Medicine 2011.; 17: 216-222
77. Mishra J, Mori K, Ma Q et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-Associated lipocalin. J Am Soc Nephrol 2004.; 15: 3073-3082
78. Mori K, Lee HT, Rapoport D et al. Endocytic delivery of lipocalin-siderophore- iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005.; 115: 610-621
79. Yan L, Borregaard N, Kjeldsen L et al. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-Associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001.; 276: 37258-37265
80. Kunugi S, Shimizu A, Kuwahara N et al. Inhibition of matrix metalloproteinases reduces ischemia-reperfusion acute kidney injury. Lab Invest 2011.; 91: 170-180
81. Lee SY, Horbelt M, Mang HE et al. MMP-9 gene deletion mitigates microvascular loss in a model of ischemic acute kidney injury. Am J Physiol Renal Physiol 2011.; 301: F101YF109
82. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003.; 73: 213-224
83. Okamura H, Tsutsi H, Komatsu T et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995.; 378: 88-91
84. Ushio S, Namba M, Okura T et al. Cloning of the cDNA for human IFNgamma- inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996.; 156: 4274-4279
85. Ghayur T, Banerjee S, Hugunin M et al. Caspase-1 processes IFNgamma- inducing factor and regulates LPS-induced IFN-gamma production. Nature 1997.; 386: 619-623
86. Gu Y, Kuida K, Tsutsui H et al. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 1997.; 275: 206-209
87. Puren AJ, Fantuzzi G, Dinarello CA. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci USA 1999.; 96: 2256-2261
88. Edelstein CL, Hoke TS, Somerset H et al. Proximal tubules from caspase- 1-deficient mice are protected against hypoxia-induced membrane injury. Nephrol Dial Transplant 2007.; 22: 1052-1061
89. Parnet P, Garka KE, Bonnert TP et al. IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J Biol Chem 1996.; 271: 3967-3970
90. Hoshino K, Tsutsui H, Kawai T et al. Cutting edge: Generation of IL- 18 receptor-deficient mice: Evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol 1999.; 162: 5041-5044
91. Torigoe K, Ushio S, Okura T et al. Purification and characterization of the human interleukin-18 receptor. J Biol Chem 1997.; 272: 25737Y 25742
92. Melnikov VY, Ecder T, Fantuzzi G et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest 2001.; 107: 1145-1152
93. He Z, Dursun B, Oh DJ et al. Macrophages are not the source of injurious interleukin-18 in ischemic acute kidney injury in mice. Am J Physiol Renal Physiol 2009.; 296: F535YF542
94. Faubel S, Ljubanovic D, Poole B et al. Peripheral CD4 T-cell depletion is not sufficient to prevent ischemic acute renal failure. Transplantation 2005.; 80: 643-649
95. Zhang H, Hile KL, Asanuma H et al. IL-18 mediates proapoptotic signaling in renal tubular cells through a Fas ligand-dependent mechanism. Am J Physiol Renal Physiol 2011.; 301: F171YF178
96. Parikh CR, Jani A, Melnikov VY et al. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004.; 43: 405-414
97. Parikh CR, Abraham E, Ancukiewicz M et al. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 2005.; 16: 3046-3052
98. Liu Y, GuoW, Zhang J et al. Urinary interleukin 18 for detection of acute kidney injury: A meta-Analysis. Am J Kidney Dis 2013. pii: S0272-6386 (13)00909-8. doi 10.1053/j.ajkd.2013.05.014
99. Corsico B, Cistola DP, Frieden C et al. The helical domain of intestinal fatty acid binding protein is critical for collisional transfer of fatty acids to phospholipid membranes. Proc Natl Acad Sci USA 1998.; 95: 12174-12178
100. Landrier JF, Thomas C, Grober J et al. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator- Activated receptor-Alpha-dependent. J Biol Chem 2004.; 279: 45512-45518
101. Kamijo A, Sugaya T, Hikawa A et al. Urinary excretion of fatty acidbinding protein reflects stress overload on the proximal tubules. Am J Pathol 2004.; 165: 1243-1255
102. Yamamoto T, Noiri E, Ono Y et al. Renal L-type fatty acid - binding protein in acute ischemic injury. J Am Soc Nephrol 2007.; 18: 2894-2902
103. Negishi K, Noiri E, Sugaya T et al. A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure. Kidney Int 2007.; 72: 348-358
104. Doi K, Noiri E, Maeda-Mamiya R et al. Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Crit Care Med 2010.; 38: 2037-2042
105. Katagiri D, Doi K, Honda K et al. Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery. Ann Thorac Surg 2012.; 93: 577-583
106. Parikh CR, Thiessen-Philbrook H, Garg AX et al. Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery. Clin J Am Soc Nephrol 2013.; 8: 1079-1088
107. Barallobre MJ, Pascual M, Del Rio JA et al. The Netrin family of guidance factors: Emphasis on Netrin-1 signalling. Brain Res Brain Res Rev 2005.; 49: 22-47
108. Ly NP, Komatsuzaki K, Fraser IP et al. Netrin-1 inhibits leukocyte migration in vitro and in vivo. Proc Natl Acad Sci USA 2005.; 102: 14729-14734
109. WangW, Reeves WB, Ramesh G. Netrin-1 and kidney injury. I. Netrin-1 protects against ischemia-reperfusion injury of the kidney. Am J Physiol Renal Physiol 2008.; 294: F739YF747
110. Mehlen P, Furne C. Netrin-1: When a neuronal guidance cue turns out to be a regulator of tumorigenesis. Cell Mol Life Sci 2005.; 62: 2599-2616
111. Ranganathan PV, Jayakumar C, Mohamed R et al. Netrin-1 regulates the inflammatory response of neutrophils and macrophages, and suppresses ischemic acute kidney injury by inhibiting COX-2-mediated PGE2 production. Kidney Int 2013.; 83: 1087-1098
112. Liu L, Xie S, Liao X et al. Netrin-1 pretreatment protects rat kidney against ischemia/reperfusion injury via suppression of oxidative stress and neuropeptide Y expression. J Biochem Mol Toxicol 2013.; 27: 231-236
113. Reeves WB, Kwon O, Ramesh G. Netrin-1 and kidney injury. II. Netrin- 1 is an early biomarker of acute kidney injury. Am J Physiol Renal Physiol 2008.; 294: F731YF738
114. Saikumar J, Hoffmann D, Kim TM et al. Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci 2012.; 129: 256-267
115. Kashani K, Al-Khafaji A, Ardiles T et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 2013.; 17: R25
116. Zhou H, Pisitkun T, Aponte A et al. Exosomal Fetuin-A identified by proteomics: A novel urinary biomarker for detecting acute kidney injury. Kidney Int 2006.; 70: 1847-1857
117. Fiehn O. Metabolomics - the link between genotypes and phenotypes. Plant Mol Biol 2002.; 48: 155-171
118. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999.; 29: 1181-1189
119. Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol 2012.; 8: 22-33
120. Portilla D, Schnackenberg L, Beger RD. Metabolomics as an extension of proteomic analysis: Study of acute kidney injury. Sem in Nephrol 2007.; 27: 609-620
121. Portilla D, Li S, Nagothu KK et al. Metabolomic study of cisplatininduced nephrotoxicity. Kidney Int 2006.; 69: 2194-2204
122. McCullough PA, Shaw AD, Haase M et al. Diagnosis of acute kidney injury using functional and injury biomarkers: Workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib Nephrol 2013.; 182: 13-29